Hac Quant Megatrend Dynamic Global Fund (ANTX)

Overview

AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a focused mission to develop treatments for rare, chronic, and serious infectious diseases. Established in 2017 and based in Menlo Park, California, AN2 Therapeutics leverages its expertise in drug development to address unmet medical needs, particularly in the domain of infectious diseases that pose significant challenges to patient health. The company's dedication to innovation is underscored by its strategic licensing agreements, such as those with Anacor Pharmaceuticals, Inc. and Brii Biosciences Limited. These partnerships empower AN2 Therapeutics to broaden its therapeutic reach, enabling the advancement of its leading compounds, including epetraborole, in key markets like China, Hong Kong, Taiwan, and Macau, alongside its global aspirations.

Products and Services

• Epetraborole

Epetraborole stands out as AN2 Therapeutics' flagship investigational drug, currently in the pivotal Phase 2/3 clinical trial stage. It is designed as a once-daily oral treatment targeting patients suffering from non-tuberculous mycobacterial lung disease, a condition that presents considerable treatment challenges due to its chronic nature and the limited effectiveness of current therapies. Rooted in AN2 Therapeutics' proprietary research and development, epetraborole represents a beacon of hope for patients in dire need of new treatment options.

• AN2-502998 (AN15368)

This investigational boron-based small molecule is another testament to AN2 Therapeutics' commitment to addressing infectious diseases with innovative solutions. Currently in the preclinical trial phase, AN2-502998 (AN15368) is being developed to tackle chronic Chagas disease, a neglected tropical disease that continues to affect millions of people worldwide, primarily in Latin America. With its unique approach and potential for efficacy, AN2-502998 offers a promising avenue for combatting Chagas disease.